Immunovant, Inc. reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported net loss was USD 75.32 million compared to USD 59.43 million a year ago. Basic loss per share from continuing operations was USD 0.52 compared to USD 0.46 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.29 USD | +4.20% | +2.59% | -35.22% |
06-03 | Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating | MT |
05-30 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.22% | 3.99B | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+35.88% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- IMVT Stock
- News Immunovant, Inc.
- Immunovant, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024